NEW YORK (GenomeWeb) – Pharmacogenomics firm OneOme said on Monday it has earned laboratory certification in five additional states, bringing the total number of states where it can offer its testing services to 49.
The states in which OneOme received certification are California, Florida, Maryland, Pennsylvania, and Rhode Island. It said it will seek certification in New York this year.
OneOme will begin accepting orders from the five new states for its RightMed pharmacogenomic test immediately. RightMed analyzes patients' genetic profiles to assess whether they are responders to specific medications.
The test, which costs $249, covers 22 genes and can help healthcare providers make evidence-based decisions for more than 340 drugs, OneOme said, adding it has also developed a platform to generate the interpretive drug report using genotype or sequence data elsewhere.